SCHEDULE 13G/A: ARK Investment Management Discloses Significant 10.70% Stake in Twist Bioscience Corp

ARK Investment Management LLC has disclosed a beneficial ownership of 10.70% in Twist Bioscience Corp, holding over 6.38 million shares as of February 28, 2025.

Summary

• ARK Investment Management LLC, a Delaware-based investment adviser, has filed a Schedule 13G indicating beneficial ownership in Twist Bioscience Corp.
• As of February 28, 2025, ARK Investment Management LLC beneficially owns 6,382,166 shares of Twist Bioscience Corp's Common Stock.
• This ownership represents 10.70% of the class of securities outstanding.
• ARK Investment Management LLC holds sole voting power over 6,077,112 shares and shared voting power over 107,575 shares.
• The firm also holds sole dispositive power over 6,382,166 shares and no shared dispositive power.
• The filing certifies that the securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 7

Explanation: The disclosure of a significant stake by a prominent investment firm like ARK Investment Management is generally viewed positively by the market, indicating confidence in the company's prospects, even if it's a passive investment.

Positives

• A significant stake (10.70%) by a prominent investment firm like ARK Investment Management LLC can be viewed as a vote of confidence in Twist Bioscience Corp's long-term prospects and strategic direction.
• The passive nature of the 13G filing indicates that ARK's investment is for ordinary course business and not an attempt to influence or control the company, suggesting a belief in current management and strategy.

Risks

• The value of ARK Investment Management's stake is subject to market fluctuations and the performance of Twist Bioscience Corp's stock.
• While the filing indicates a passive investment, any future changes in ARK's holdings (e.g., significant selling) could impact the stock price.

Future Outlook

This Schedule 13G filing does not contain forward-looking statements or guidance regarding Twist Bioscience Corp's future financial performance or operational outlook. It solely reports a change in beneficial ownership by a passive investor.

Industry Context

ARK Investment Management is known for its focus on disruptive innovation, particularly in sectors like biotechnology and genomics. Their significant investment in Twist Bioscience, a company specializing in synthetic DNA and gene synthesis, aligns with ARK's broader investment thesis in high-growth, innovative technology companies within the life sciences sector. This investment suggests ARK's continued confidence in the long-term potential of synthetic biology and its applications.

Stakeholder Impact

• Shareholders: The disclosure of a significant stake by a reputable investment firm like ARK Investment Management may instill greater confidence among existing shareholders and attract new investors, potentially leading to positive share price movement.
• Management: While a passive investment, it signifies external validation of the company's strategy and potential, which can be a morale boost for management and employees.

Key Dates

Keywords

Twist Bioscience Corp, ARK Investment Management, Schedule 13G, Beneficial Ownership, Common Stock, Investment Adviser, Biotechnology, Synthetic Biology